REDUCED PHOSPHATE INTAKE IN "NORMO-PHOSPHATEMIC" CHRONIC KIDNEY DISEASE PATIENTS

减少“正磷酸盐”慢性肾病患者的磷酸盐摄入量

• 批准号: 7374764
• 负责人: MYLES S WOLF
• 金额: $ 2.42万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374764
• 关键词: REDUCED; PHOSPHATE; INTAKE; NORMO; PHOSPHATEMIC

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purposes of this proposal are to (1) establish the primacy of phosphate loading, even without hyperphosphatemia, in the development of secondary hyperparathyroidism and (2) develop pilot data of a treatment strategy that manipulates phosphate loading in an effort to ameliorate the development of secondary hyperparathyroidism by increasing endogenous calcitriol levels, which itself along with decreased phosphate levels may be potential survival factors.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本提案的目的是（1）确立磷酸盐负荷在继发性甲状旁腺功能亢进发生中的首要地位，即使没有高磷酸盐血症;（2）开发治疗策略的初步数据，该策略通过增加内源性骨化三醇水平来操纵磷酸盐负荷，以改善继发性甲状旁腺功能亢进的发生，内源性骨化三醇水平本身沿着磷酸盐水平降低可能是潜在的生存因素。